每经记者|林姿辰 每经编辑|魏官红9月12日开盘,药捷安康(02617.HK)一路上涨,盘中最高达到251.40港元/股,总市值一度逼近千亿港元,截至当日收盘,公司市值为764.03亿港元。此时,距离公司登陆港交所,刚过去不到三个月。与多数Biotech(生物科技公司)一样,药捷安康目前还没有商业化产品,今年上半年,公司的营业收入为0,亏损1.23亿元,公司主要管线包括6款临床阶段候选产品及...
Source Link每经记者|林姿辰 每经编辑|魏官红9月12日开盘,药捷安康(02617.HK)一路上涨,盘中最高达到251.40港元/股,总市值一度逼近千亿港元,截至当日收盘,公司市值为764.03亿港元。此时,距离公司登陆港交所,刚过去不到三个月。与多数Biotech(生物科技公司)一样,药捷安康目前还没有商业化产品,今年上半年,公司的营业收入为0,亏损1.23亿元,公司主要管线包括6款临床阶段候选产品及...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.